David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opening Session Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Aug

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opening Session Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

ASTRO Updates Guideline on Radiation Therapy for Pancreatic Cancer

ASCO Remembers Dr. Harold P. Freeman, Preeminent Health Equity Expert and Pioneer of Patient Navigation

WashU Medicine Appoints New Chief of Head and Neck Surgery

Colorectal Cancer May Cause Peripheral Neuropathy Before Treatment Preclinical Study Finds

Expanded EHR Data May Improve Prediction of Early Adverse Events After AML Induction Chemotherapy